Single-cell and bulk RNA sequencing reveal cancer-associated fibroblast heterogeneity and a prognostic signature in prostate cancer

被引:6
|
作者
Liu, Wen [1 ,2 ]
Wang, Miaomiao [1 ,2 ]
Wang, Miao [1 ]
Liu, Ming [1 ,2 ]
机构
[1] Chinese Acad Med Sci, Beijing Hosp, Inst Geriatr Med, Natl Ctr Gerontol,Dept Urol, 1 DaHua Rd, Beijing 100730, Peoples R China
[2] Chinese Acad Med Sci, Peking Union Med Coll, Grad Sch, Beijing, Peoples R China
关键词
cancer-associated fibroblast; prognostic signature; prostate cancer; single-cell; MACROPHAGES; PROGRESSION; INFERENCE;
D O I
10.1097/MD.0000000000034611
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Cancer-associated fibroblasts (CAFs), the central players in the tumor microenvironment (TME), can promote tumor progression and metastasis via various functions. However, the properties of CAFs in prostate cancer (PCa) have not been fully assessed. Therefore, we aimed to examine the CAF characteristics in PCa and construct a CAF-derived signature to predict PCa prognosis. CAFs were identified using single-cell RNA sequencing (scRNA-seq) data from 3 studies. We performed the FindAllMarkers function to extract CAF marker genes and constructed a signature to predict the biochemical relapse-free survival (bRFS) of PCa in the Cancer Genome Atlas (TCGA) cohort. Subsequently, different algorithms were applied to reveal the differences of the TME, immune infiltration, treatment responses in the high- and low-risk groups. Additionally, the CAF heterogeneity was assessed in PCa, which were confirmed by the functional enrichment analysis, gene set enrichment analysis (GSEA), and AUCell method. The scRNA-seq analysis identified a CAF cluster with 783 cells and determined 183 CAF marker genes. Cell-cell communication revealed extensive interactions between fibroblasts and immune cells. A CAF-related prognostic model, containing 7 genes (ASPN, AEBP1, ALDH1A1, BGN, COL1A1, PAGE4 and RASD1), was developed to predict bRFS and validated by 4 independent bulk RNA-seq cohorts. Moreover, the high-risk group of the signature score connected with an immunosuppressive TME, such as a higher level of M2 macrophages and lower levels of plasma cells and CD8(+) T cells, and a reduced reaction rate for immunotherapy compared with low-risk group. After re-clustering CAFs via unsupervised clustering, we revealed 3 biologically distinct CAF subsets, namely myofibroblast-like CAFs (myCAFs), immune and inflammatory CAFs (iCAFs) and antigen-presenting CAFs (apCAFs). In conclusion, the CAF-derived signature, the first of its kind, can effectively predict PCa prognosis and serve as an indicator for immunotherapy. Furthermore, our study identified 3 CAF subpopulations with distinct functions in PCa.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] Integrated single-cell and bulk RNA sequencing analyses reveal a prognostic signature of cancer-associated fibroblasts in head and neck squamous cell carcinoma
    Yang, Yichen
    Ma, Ben
    Han, Litao
    Xu, Weibo
    Du, Xiaoxue
    Wei, Wenjun
    Liao, Tian
    Ji, Qinghai
    Qu, Ning
    Wang, Yu
    FRONTIERS IN GENETICS, 2022, 13
  • [2] Development of a Cancer-Associated Fibroblast-Related Prognostic Model in Breast Cancer via Bulk and Single-Cell RNA Sequencing
    Hu, Jing
    Jiang, Yueqiang
    Wei, Qihao
    Li, Bin
    Xu, Sha
    Wei, Guang
    Li, Pin
    Chen, Wei
    Lv, Wenzhi
    Xiao, Xianjin
    Lu, Yaping
    Huang, Xuan
    BIOMED RESEARCH INTERNATIONAL, 2022, 2022
  • [3] Single-cell RNA sequencing and spatial transcriptomics reveal the heterogeneity and intercellular communication of cancer-associated fibroblasts in gastric cancer
    Zhang, Xijie
    Ren, Bo
    Liu, Bo
    Wang, Rui
    Li, Sen
    Zhao, Yuzhou
    Zhou, Wence
    JOURNAL OF TRANSLATIONAL MEDICINE, 2025, 23 (01)
  • [4] Cancer-associated fibroblast-related prognostic signature predicts prognosis and immunotherapy response in pancreatic adenocarcinoma based on single-cell and bulk RNA-sequencing
    Chen, Yajun
    Deng, Qican
    Chen, Hui
    Yang, Jianguo
    Chen, Zhenzhou
    Li, Juncai
    Fu, Zhongxue
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [5] Cancer-associated fibroblast-related prognostic signature predicts prognosis and immunotherapy response in pancreatic adenocarcinoma based on single-cell and bulk RNA-sequencing
    Yajun Chen
    Qican Deng
    Hui Chen
    Jianguo Yang
    Zhenzhou Chen
    Juncai Li
    Zhongxue Fu
    Scientific Reports, 13
  • [6] Single-cell RNA Sequencing Analysis Reveals Cancer-associated Fibroblast Signature for Prediction of Clinical Outcomes and Immunotherapy in Gastric Cancer
    Li, Xiaoxiao
    Tang, Bo
    Yujie, Ouyang
    Xu, Chuan
    Yuan, Shuanghu
    JOURNAL OF IMMUNOTHERAPY, 2025, 48 (02) : 63 - 77
  • [7] Integrated single-cell and bulk RNA sequencing analysis identifies a cancer-associated fibroblast-related gene signature for predicting survival and therapy in gastric cancer
    Zhou, Zhiyang
    Guo, Sixuan
    Lai, Shuhui
    Wang, Tao
    Du, Yao
    Deng, Junping
    Zhang, Shun
    Gao, Ge
    Zhang, Jiangnan
    BMC CANCER, 2023, 23 (01)
  • [8] Integrated single-cell and bulk RNA sequencing analysis identifies a cancer-associated fibroblast-related gene signature for predicting survival and therapy in gastric cancer
    Zhiyang Zhou
    Sixuan Guo
    Shuhui Lai
    Tao Wang
    Yao Du
    Junping Deng
    Shun Zhang
    Ge Gao
    Jiangnan Zhang
    BMC Cancer, 23
  • [9] A novel cancer-associated fibroblast signature for kidney renal clear cell carcinoma via integrated analysis of single-cell and bulk RNA-sequencing
    Lu, Ling
    Feng, Huaguo
    Dai, Guohua
    Liu, Shuangquan
    Feng, Yi
    Tan, Haoyang
    Zhang, Xian
    Hong, Guoqing
    Lai, Xing
    DISCOVER ONCOLOGY, 2024, 15 (01)
  • [10] Identification and validation of cancer-associated fibroblast-related subtypes and the prognosis model of biochemical recurrence in prostate cancer based on single-cell and bulk RNA sequencing
    Li, Tiewen
    Zhou, Zeng
    Xie, Zhiwen
    Fan, Xuhui
    Zhang, Yichen
    Zhang, Yu
    Song, Xiaodong
    Ruan, Yuan
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (13) : 11379 - 11395